Title : Efficacy and safety evaluation of safinamide as an add-on treatment to levodopa for parkinson's disease.

Pub. Date : 2022 Feb

PMID : 34597253






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 AREAS COVERED: : Safinamide is a highly selective and reversible monoamine oxidase B inhibitor introduced in the European Union, Japan, and the United States as an adjunctive agent to levodopa in PD patients with motor fluctuation. safinamide monoamine oxidase B Homo sapiens